Structure via PubChem · Public domain (PubChem)
erdafitinib
Sign in to saveAlso known as compound 4 [WO2011135376], JNJ-42756493
Erdafitinib, sold under the brand name Balversa, is an anti-cancer medication. It is a small molecule inhibitor of fibroblast growth factor receptor (FGFR) used for the treatment of cancer. FGFRs are a subset of tyrosine kinases which are unregulated in some tumors and influence tumor cell differentiation, proliferation, angiogenesis, and cell survival. Astex Pharmaceuticals discovered the drug and licensed it to Janssen Pharmaceuticals for further development.
Chemical data
- Formula
- C25H30N6O2
- Molecular weight
- 446.5 g/mol
- IUPAC name
- N'-(3,5-dimethoxyphenyl)-N'-[3-(1-methylpyrazol-4-yl)quinoxalin-6-yl]-N-propan-2-ylethane-1,2-diamine
- SMILES
- CC(C)NCCN(C1=CC2=NC(=CN=C2C=C1)C3=CN(N=C3)C)C4=CC(=CC(=C4)OC)OC
- InChIKey
- OLAHOMJCDNXHFI-UHFFFAOYSA-N
- XLogP
- 3.2
- Polar surface area
- 77.3 Ų
- H-bond donors
- 1
- H-bond acceptors
- 7
- Formal charge
- 0
via PubChem
Drug data · ChEMBL
- Max clinical phase
- Approved
- Molecule type
- Small molecule
- First approval
- 2019
- Admin. routes
- oral
- Indications
- neoplasm, hepatocellular carcinoma, lymphoma, multiple myeloma
via ChEMBL · EBI
Wikidata facts
- Subclass of
- chemical compound
- Mass
- 446.243
- Has use
- medication
Show 4 more facts
- canonical SMILES
- CC(C)NCCN(C1=CC2=NC(=CN=C2C=C1)C3=CN(N=C3)C)C4=CC(=CC(=C4)OC)OC
- subject has role
- protein kinase inhibitors
- chemical formula
- C₂₅H₃₀N₆O₂
- medical condition treated
- transitional cell carcinoma
via Wikidata · CC0
~6 min read
Encyclopedic overview
8 sectionsContents
- Medical uses
- Side effects
- History
- Society and culture
- Legal status
- Research
- References
- External links
Erdafitinib, sold under the brand name Balversa, is an anti-cancer medication. It is a small molecule inhibitor of fibroblast growth factor receptor (FGFR) used for the treatment of cancer. FGFRs are a subset of tyrosine kinases which are unregulated in some tumors and influence tumor cell differentiation, proliferation, angiogenesis, and cell survival. Astex Pharmaceuticals discovered the drug and licensed it to Janssen Pharmaceuticals for further development.
== Medical uses == In the United Statest, erdafitinib is indicated for the treatment of adults with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations whose disease has progressed on or after at least one line of prior systemic therapy.
Excerpted from Wikipedia’s “erdafitinib” article, available under the CC BY-SA 4.0 licence.